retatrutide phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Availability: Everything You Need

Research published in the New England Journal of Medicine demonstrates that semaglutide achieves remarkable weight reduction: participants lost an average of 14.9% of their body weight at 68 weeks with half achieving at least 15% weight loss and nearly one third losing 20% or more

Injectable tirzepatide bypasses the stomach entirely, delivering the medication directly into subcutaneous tissue, making it a mechanistically sound option for post-bariatric candidates

I want to avoid surgery and start him on peptides

that gaunt, instantly aged appearance of patients who lose volume and fat from their faces as a result of the kind of drastic weight loss that Ozempic delivers Sarcopenia Multiple endocrine neoplasia syndrome type 2 Diabetic retinopathy Hypoglycemia Increased heart rate Hair loss Development of eating disorders, especially given that semaglutide is now authorized for use in children Urticaria, a raised or itchy skin rash Infertility, increased risk of miscarriage, low birth weight and incidences of visceral (kidney, liver, heart, blood vessels) and skeletal (sternebra, cranial bones, vertebra, ribs) fetal abnormalities were observed Hypersensitivity reactions, including anaphylaxis Its worth noting that approximately 39% of semaglutide-induced weight loss is actually muscle loss, not fat loss

Diarrhea Diarrhea affects about 29.7% of semaglutide 2.4 mg users in the STEP trials versus 15.9% on placebo